Mental Health Book



Aka: Valbenazine, Ingrezza
  1. Indications
    1. Tardive Dyskinesia
  2. Mechanism
    1. Selective inhibitor of vesicular monoamine transporter-2 (VMAT2)
    2. Decreases Dopamine release at nerve endings (Synapse)
  3. Efficacy
    1. Reduces symptoms by 50% with 6 weeks of treatment (Number Needed to Treat: 4)
  4. Dosing
    1. Valbenazine (Ingrezza)
      1. Start 40 mg once daily and may increase to 80 mg after 1 week
      2. Target: 40-80 mg once daily
    2. Very expensive ($5000 per month)
  5. Drug Interactions
    1. Strong CYP3A4 Inhibitors (e.g. Clarithromycin, Itraconazole)
      1. Increases Valbenazine levels
      2. Limit maximum Valbenazine dose to 40 mg daily
    2. Strong CYP3A4 inducers (e.g. Carbamazepine, Phenytoin)
      1. Decreases levels
      2. Avoid while taking Valbenazine
    3. Strong CYP2D6 Inhibitors (e.g. Fluoxetine, Paroxetine)
      1. May increase Valbenazine levels and may require reduced Valbenazine doses
  6. Metabolism
    1. Liver and renal metabolism
    2. Avoid Valbenazine use in GFR <30 ml/min
    3. Consider reduced Valbenazine dose in liver Impairment
  7. Adverse Effects
    1. QT Prolongation
    2. Somnolence
  8. Safety
    1. Pregnancy safety is unknown
  9. References
    1. (2017) Presc Lett 24(6): 36
    2. LoVecchio (2018) Crit Dec Emerg Med 32(6): 32

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree